GlassScriptPhysician profile
Arash Tirandaz
NPI 1790723245
$7,444.24
in general payments reported to CMS, 2019-2025
45 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $843 · 2021: $1,180 · 2022: $1,401 · 2023: $1,569 · 2024: $423 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $160 · Entertainment: $17.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.16 |
| Education | $159.98 |
| Entertainment | $17.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,315.72 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,006.52 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $525.10 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $441.83 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $418.36 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $399.82 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.68 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.84 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $314.19 | 2019-2023 | Steglatro, Belsomra |
| Abbott Laboratories | $281.33 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $220.93 | 2019-2022 | |
| Amarin Pharma, INC. | $188.20 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $148.85 | 2019-2023 | |
| Lilly USA, LLC | $143.98 | 2019-2024 | Jardiance, Mounjaro |
| Pfizer INC. | $130.59 | 2019-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $126.41 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $106.94 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $91.02 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $77.57 | 2019-2023 | Livalo |
| Biohaven Pharmaceuticals, INC. | $76.84 | 2021 | |
| Eisai INC. | $56.28 | 2019-2020 | |
| Medtronic, INC. | $51.49 | 2022-2025 | Intellis Adaptivestim, Venaseal |
| Radius Health, INC. | $49.43 | 2019-2023 | Tymlos |
| Sunovion Pharmaceuticals INC. | $44.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.64 | 2022 | |
| Esperion Therapeutics, INC. | $35.88 | 2020-2021 | |
| Shire North American Group INC | $33.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.44 | 2019 | |
| Beta Bionics, INC. | $31.20 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Arbor Pharmaceuticals, INC. | $30.74 | 2021 | |
| Gilead Sciences, INC. | $30.01 | 2019 | |
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $26.64 | 2019 | |
| Sumitomo Pharma America, INC. | $26.62 | 2023 | Gemtesa |
| Currax Pharmaceuticals LLC | $26.29 | 2021-2023 | Contrave |
| Dexcom, INC. | $24.56 | 2025 | Dexcom G6 Transmitter |
| Medtronic USA, INC. | $21.37 | 2019 | |
| Boston Scientific Corporation | $20.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.29 | 2019 | |
| Exact Sciences Corporation | $18.10 | 2023 | Cologuard Collection Kit |
| Optos, INC. | $17.56 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Renalytix Ai, INC. | $17.53 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ibsa Pharma INC. | $14.09 | 2025 | Licart, Flector, Tirosint |
| Novartis Pharmaceuticals Corporation | $13.98 | 2022 | |
| Allergan, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Tirandaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.